PMID- 16903979
OWN - NLM
STAT- MEDLINE
DCOM- 20070403
LR  - 20071115
IS  - 1464-2662 (Print)
IS  - 1464-2662 (Linking)
VI  - 7
IP  - 6
DP  - 2006 Sep
TI  - Influence of a monocyte chemoattractant protein 1 mutated allele on the response 
      to protease inhibitor-based antiretroviral therapy.
PG  - 356-60
AB  - BACKGROUND: Antiretroviral drug efficacy has been widely studied in relation to 
      viral factors. Mutations in the HIV co-receptors and their natural chemokines, 
      however, may be critical in HIV infection and treatment response. We compared the 
      efficacy of protease inhibitor (PI) treatment among PI-naive patients grouped 
      according to whether they carried the chemokine CC motif receptor 2 (CCR-2) 64I 
      and monocyte chemoattractant protein 1 (MCP-1)-2518G alleles. METHODS AND 
      RESULTS: HIV-infected patients who were PI-naive were selected for the study 
      (n=164) but there was no restriction on lymphocyte CD4 count or plasma HIV viral 
      load. Follow-up was for the first 24 months of treatment. Clinical and laboratory 
      data were obtained every 3 months. All the participants were genotyped for the 
      MCP-1-2518G, CCR-2 64I, CCR-5Delta32 and stromal derived factor 1 (SDF1) 3'A 
      mutated alleles. The results indicated that patients carrying the mutated allele 
      of MCP-1 had a higher mean CD4 cell count throughout the follow-up period than 
      those with the common allele (P=0.01). Also, patients with the MCP-1 and CCR-2 
      mutated alleles were more likely to continue to have an undetectable viral load 
      following treatment (P=0.05). CONCLUSION: A better response to PI treatment 
      appears to be conferred by mutations in the host MCP-1 and CCR-2 genes, and may 
      be related to the cellular axis-of-entry used by the retrovirus.
FAU - Coll, B
AU  - Coll B
AD  - Servei de Medicina Interna, Hospital Universitari de Sant Joan, Reus, Spain. 
      bcoll@grupsagessa.com
FAU - Alonso-Villaverde, C
AU  - Alonso-Villaverde C
FAU - Parra, S
AU  - Parra S
FAU - Rabassa, A
AU  - Rabassa A
FAU - Martorell, L
AU  - Martorell L
FAU - Joven, J
AU  - Joven J
FAU - Masana, L
AU  - Masana L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Receptors, CCR2)
RN  - 0 (Receptors, Chemokine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Alleles
MH  - *Antiretroviral Therapy, Highly Active
MH  - CD4 Lymphocyte Count
MH  - Chemokine CCL2/*genetics
MH  - Female
MH  - HIV Infections/*drug therapy/*genetics/immunology/virology
MH  - HIV Protease Inhibitors/*therapeutic use
MH  - HIV-1/*drug effects/physiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Receptors, CCR2
MH  - Receptors, Chemokine/genetics
MH  - Treatment Outcome
MH  - Viral Load
EDAT- 2006/08/15 09:00
MHDA- 2007/04/04 09:00
CRDT- 2006/08/15 09:00
PHST- 2006/08/15 09:00 [pubmed]
PHST- 2007/04/04 09:00 [medline]
PHST- 2006/08/15 09:00 [entrez]
AID - HIV392 [pii]
AID - 10.1111/j.1468-1293.2006.00392.x [doi]
PST - ppublish
SO  - HIV Med. 2006 Sep;7(6):356-60. doi: 10.1111/j.1468-1293.2006.00392.x.